Research Peptide Comparison
Retatrutide 10mg and Tirzepatide 30mg are both GLP-1 Peptides research peptides available from Neovia Peptides. This comparison highlights the key differences in specifications, pricing, and availability to help inform your research decisions.
Retatrutide is a 39-amino-acid synthetic peptide that functions as a triple agonist at the GLP-1, GIP and glucagon receptors. By engaging all three incretin and glucagon pathways at once, it has been investigated for its combined effects on insulin secretion, energy expenditure, lipolysis and hepatic glucose output, and is one of the most-studied triple agonists in modern metabolic research.
Compared to Tirzepatide 30mg, Retatrutide 10mg is priced at £69.50 with 99%+ verified purity. Its CAS registry number is 2381089-83-2. It has a molecular weight of 4875.42 g/mol.
Retatrutide 10mg is available in 10mg, 20mg, 40mg and ships with a full Certificate of Analysis from Janoshik Analytical. At £24.49 less than Tirzepatide 30mg, it is the more affordable option in this comparison.
Tirzepatide is a synthetic 39-residue peptide acting as a dual agonist at the GIP and GLP-1 receptors, the two principal incretin targets involved in postprandial glucose handling and appetite regulation. Its combined action on both receptors has made it a central reference compound in studies of insulin response, glucagon dynamics and metabolic adaptation, and one of the most-studied dual incretin agonists in modern metabolic research.
Compared to Retatrutide 10mg, Tirzepatide 30mg is priced at £93.99 with 99.5%+ verified purity. Its CAS registry number is 2023788-19-2. It has a molecular weight of 4813.52 g/mol.
Tirzepatide 30mg is available in 15mg, 30mg, 60mg and ships with a full Certificate of Analysis from Janoshik Analytical. It is priced £24.49 higher than Retatrutide 10mg.
All products sold by Neovia Peptides are strictly for in-vitro research and laboratory use only. Not intended for human or veterinary use, food additives, drugs, or cosmetics. By purchasing from this website, you agree that you understand and accept these terms.
